Nuwellis, Inc. — 2021 Form 10-K Summary
Business context and reporting period
Fiscal year ended December 31, 2021. Nuwellis develops, manufactures and sells the Aquadex ultrafiltration system for patients with fluid overload unresponsive to medical management, including diuretics. Its commercial focus includes critical care, heart failure and pediatric patients weighing at least 20 kg. Revenue is primarily from disposable circuits and catheters, with sales mainly to U.S. hospitals and clinics.
Financial performance and liquidity
| Metric | 2021 | 2020 |
|---|---|---|
| Net sales | $7.921 million | $7.441 million |
| Gross profit / margin | $4.491 million / 56.7% | $4.057 million / 54.5% |
| Operating expenses | $24.017 million | $21.085 million |
| Loss from operations | $(19.526) million | $(17.028) million |
| Net loss | $(19.578) million | $(15.836) million |
| Operating cash used | $(17.880) million | $(16.572) million |
| Cash and cash equivalents at year-end | $24.205 million | $14.437 million |
Revenue increased 6.5%. Gross margin improved, primarily from higher volumes and favorable mix, but higher SG&A and R&D contributed to a larger operating and net loss. R&D included a $428,160 non-refundable technology license fee. The 2020 results included a $1.202 million gain from dissolution of an Australian subsidiary. Loss per share was $(2.87) versus $(10.67); the comparison is affected by a substantial increase in weighted-average shares and preferred-stock deemed dividends, and does not indicate improved net earnings.
At year-end, current assets were $28.126 million and current liabilities were $3.307 million. Total liabilities were $4.470 million, including operating and finance lease liabilities; the filing reports no material capital-expenditure commitments or off-balance-sheet arrangements. Cash used in financing was more than offset by equity proceeds: 2021 net proceeds were approximately $18.9 million from the March offering and $9.0 million from the September offering. Shares outstanding increased from 2.736 million to 10.538 million during 2021.
Material changes, outlook and risks
- Management reported that 2021 sales benefited from console sales to new and existing customers and higher circuit sales, but were constrained by pandemic-related hospital access and procedure-volume effects and a change in COVID-related treatment protocols.
- Omicron-related hospital prioritization reduced anticipated fourth-quarter 2021 revenue. The filing does not provide a clear numerical fourth-quarter revenue value or quantified forward revenue guidance.
- Management expects continued losses and says existing capital resources are expected to support its operating plan through June 30, 2023, while warning there is no assurance. Additional financing may be needed and may be unavailable or dilutive. The auditor identified the going-concern assessment as a critical audit matter; the financial statements received an unmodified audit opinion.
- Key business risks include reliance on one commercial product, customer concentration (the ten largest customers generated 51.4% of 2021 revenue; the largest generated 12.3%), limited market adoption, COVID-related access and procedure disruption, supplier and manufacturing constraints, and uncertain reimbursement. CMS had not issued a favorable national coverage determination for Aquadex; a dedicated outpatient therapeutic-ultrafiltration CPT code became effective January 1, 2022.
- Clinical evidence is mixed: the filing describes favorable findings in some ultrafiltration studies and limitations or adverse renal-function findings in others. Nuwellis launched the REVERSE-HF randomized trial in December 2021, with enrollment expected to begin in 2022, and continued its pediatric registry and product-development programs.
- The company reported no material pending legal proceedings. Management stated disclosure controls and internal control over financial reporting were effective; the auditor did not attest to internal-control effectiveness.
Most important facts for investors to verify
- Whether revenue growth and gross-margin improvement continue despite hospital access, procedure-volume and customer-concentration risks.
- Cash burn, financing needs and actual runway relative to management’s June 30, 2023 estimate; assess potential equity dilution and warrant or preferred-stock terms.
- Progress, enrollment and results of REVERSE-HF and pediatric studies, and whether evidence supports broader adoption.
- Actual reimbursement coverage and commercial impact of the new CPT code, particularly in outpatient settings.
- Execution of product development and manufacturing plans, including supplier availability, quality requirements and EU regulatory transition deadlines.